EP4559527A2 — Manufacture of a crystalline pharmaceutical product
Assigned to Orion Oyj · Expires 2025-05-28 · 1y expired
What this patent protects
The present invention relates to crystalline particles of N-((5)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) having specific surface area (SSA) in the range from about 8 to about 16 m<sup>2</sup>/g, pref…
USPTO Abstract
The present invention relates to crystalline particles of N-((5)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) having specific surface area (SSA) in the range from about 8 to about 16 m<sup>2</sup>/g, preferably from about 10 to about 15 m<sup>2</sup>/g, and to the method for the preparation of such particles. Compound (I) is a potent androgen receptor (AR) modulator which is useful as a medicament for example in the treatment of prostate cancer.
Drugs covered by this patent
- Nubeqa (darolutamide) · Bayer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.